Announcements Trials
Browse Landscape

Phase

Phase 2 69Phase 1 62Phase 1/2 33Phase 3 9Phase NA 4Phase EARLY_PHASE1 2Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 11Thoracic 2Sarcoma 2Endocrine 1Dermatologic 1

Conditions

Gliosarcoma 2Glioblastoma 1

Interventions

Doxorubicin 7Radiotherapy 4Radiation 3Magnetic Resonance Spectroscopy 3Ifosfamide 3regorafenib 2Temozolomide 2Surgical Procedures, Operative 2Methotrexate 2Imatinib Mesylate 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2veliparib 1selinexor 1pirarubicin 1pazopanib 1niraparib 1merphos 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1capmatinib 1cabozantinib 1brigimadlin 1apatinib 1anlotinib 1Zoledronic Acid 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Temozolomide × Sarcoma × Clear all
NCT02152982 2026-04-28

Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
447 enrolled 20 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡